Compare Incyte Corporation (INCY) vs Unity Software Inc (U) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Unity Software Inc — how do they compare? Incyte Corporation trades at $112.75 (market cap $22.85B), while Unity Software Inc trades at $46.34 (market cap $20.00B). The key difference: Incyte Corporation and Unity Software Inc are close in size by market cap, and Unity Software Inc is trading nearer its 52-week high, Incyte Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Unity Software Inc for 50 Days on average.
| INCY | U | |
|---|---|---|
Market Cap | $22.85B | $20.00B |
Volume | 1,927,029 | 12,798,386 |
Sector | Health | Technology |
52-Week High | $129.93 | $49.47 |
52-Week Low | $83.80 | $17.13 |
Typical Hold Time | 33 Days | 50 Days |
Enterprise Value | $18.35B | $19.88B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $113.44, up 0.63% with a bullish technical outlook despite mixed moving average signals. The company shows strong fundamentals with $5.14B revenue, 27.71% net margin, and robust cash flow of $1.41B. Recent FDA approval for Atebrioz and pipeline expansion beyond JAKAFI position the company for growth, with analysts projecting $5.8B revenue and $1.6B net income for 2026.
The investment case centers on Incyte's successful diversification strategy and strong profitability metrics, though investors face risks from JAKAFI patent expiration in 2029 and near-term earnings volatility. With 52% analyst buy ratings and a $132.43 consensus price target representing 17% upside, the stock offers growth potential but requires monitoring of pipeline execution.
Unity Software (U) trades at $45.44, up 1.09% with bullish technical momentum and strong analyst support. The stock shows improving fundamentals with revenue stabilizing around $1.8B and narrowing losses, though profitability remains negative. Recent news highlights Meta VR partnership driving investor optimism, with technical indicators showing the stock testing resistance near $46.
Unity presents a growth story with improving cash flow and strategic partnerships, but faces execution risks amid persistent losses. With 82% analyst buy ratings and a $46.54 price target, Wall Street sees upside potential, though investors must weigh high valuation multiples against the company's path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Unity Software Inc
Unity Software Inc provides a software platform for creating and operating interactive, real-time 3D content. The platform can be used to create, run and monetize interactive, real-time 2D and 3D content for mobile phones, tablets, PCs, consoles, and augmented and virtual reality devices. The business is spread across the United States, Greater China, EMEA, APAC and Other Americas, of which key revenue is derived from the EMEA region. The products are used in the gaming industry, architecture and construction sector, animation industry, and designing sector.
Read more on U →
